Jubilant Pharmova Ltd - 530019 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Jubilant Pharmova's promoter group, comprising Hari Shanker Bhartia Family Trust and Shyam Sunder Bhartia Family Trust, created a pledge on 12.68% of the company's total equity shares on June 17, 2026. This action involves 38,969,300 equity shares.
Jun 19 2026 17:45:20
Jubilant Pharmova Ltd - 530019 - Completion Of USFDA Inspection
Jubilant Pharmova's subsidiary, Jubilant HollisterStier (JHS) CMO business, completed a USFDA inspection at its Spokane, WA facility. The inspection resulted in 8 observations, none of which were related to sterility assurance concerns, with JHS committed to responding within 15 business days.
Jun 19 2026 01:06:51
Jubilant Pharmova Ltd - 530019 - USFDA Inspection Update - Contract Manufacturing Facility At Montreal, Canada
Jubilant Pharmova's subsidiary JHSGP received a USFDA Warning Letter for its contract manufacturing facility in Kirkland, Canada, following an inspection. The company has initiated corrective actions and continues operations under enhanced controls.
May 29 2026 21:10:17
Jubilant Pharmova Ltd - 530019 - Earnings Call Transcript
Jubilant Pharmova reported FY26 revenue of Rs.8,280 cr (up 14% YoY) and normalized PAT of Rs.442 cr (up 7% YoY). Management expects growth momentum to strengthen in FY27, with EBITDA margins improving in H2, driven by new product launches and operational efficiencies.
May 27 2026 20:24:53
Read More